Denmark
· Delayed Price · Currency is DKK Gubra Company Description
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally.
The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging.
The company has a partnership and collaboration with Boehringer Ingelheim to discover novel peptides for the treatment of obesity.
Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| Country | Denmark |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 220 |
| CEO | Henrik Blou |
Contact Details
Address: Hørsholm Kongevej 11B Horsholm, 2970 Denmark | |
| Phone | 45 31 52 26 50 |
| Website | gubra.dk |
Stock Details
| Ticker Symbol | GUBRA |
| Exchange | Copenhagen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0062266474 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Henrik Blou | Chief Executive Officer |
| Jacob Jelsing | Co-Founder and Chair of the Board |
| Kristian Borbos | Chief Financial Officer |
| Kristoffer Rigbolt | Chief Technology Officer |
| Louise Schjellerup Dalboge | Chief Science Officer |
| Trine Nygaard Hamann | Chief Business Officer |
| Mads Axelsen | Chief Medical Officer |
| Margit Bloch Avlund | Head of CSR |